NCT Number: NCT04734730
Phase: Phase 2
Trial Summary: This phase II trial studies the effect of talazoparib with androgen deprivation therapy and abiraterone in treating castration sensitive prostate cancer patients. Talazoparib is an – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Acronym:
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives